Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Adaptive Biotechnologies Corp (ADPT)
NASDAQ:ADPT
RESEARCH TOOLSreports
ADPT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.28 - $8.74
Previous CloseN/A
Volume480.81K
Average Volume (3M)1.57M
Market Cap
$1.23B
Enterprise Value$736.28M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.43
Next Earnings
Apr 30, 2025EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.08
Shares Outstanding147,579,480
10 Day Avg. Volume1,653,150
30 Day Avg. Volume1,565,824
Standard Deviation0.17
R-Squared0.22
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.93
Price to Cash Flow (P/CF)-11.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.60
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit7.77
Enterprise Value/Ebitda-4.50
Forecast
1Y Price Target
$8.79Price Target Upside5.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
---
Adaptive Biotechnologies News
PremiumCompany Announcements
Adaptive Biotechnologies Shines in 2024 Earnings Call
PremiumCompany Announcements
Adaptive Biotechnologies Reports 2024 Financial Performance
---
Bulls Say, Bears Say
Bulls Say
EarningsADPT delivers solid Q4 results, sets what looks like a more achievable bar than in prior years, and raises the price target to $10.
Financial PerformanceADPT holds $256M of cash on the balance sheet, providing a solid financial position.
Market ConfidenceClonoSEQ is a market-leading assay, and Adaptive Biotechnologies has received a CMS price increase, signaling strong confidence in its unique MRD test.
Bears Say
Operational ChallengesCaution around speed of trial completion and delays due to political risk on FDA disruption of trial timing under new leadership.
RevenueImmune Medicine revenue decreased by 51% year over year, with a significant decline in Genentech amortization and lower pharma and academic services revenue.
Revenue ExpectationsImmune Medicine revenues came in below expectations as aggressive cost-out hit.
---
Ownership Overview
4.18% Insiders
13.84% Mutual Funds
0.26% Other Institutional Investors
64.09% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ADPT FAQ
What was Adaptive Biotechnologies Corp’s price range in the past 12 months?
Adaptive Biotechnologies Corp lowest stock price was $2.28 and its highest was $8.74 in the past 12 months.
What is Adaptive Biotechnologies Corp’s market cap?
Adaptive Biotechnologies Corp’s market cap is $1.23B.
When is Adaptive Biotechnologies Corp’s upcoming earnings report date?
Adaptive Biotechnologies Corp’s upcoming earnings report date is Apr 30, 2025 which is in 72 days.
How were Adaptive Biotechnologies Corp’s earnings last quarter?
Adaptive Biotechnologies Corp released its earnings results on Feb 11, 2025. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.256 by $0.026.
Is Adaptive Biotechnologies Corp overvalued?
According to Wall Street analysts Adaptive Biotechnologies Corp’s price is currently Undervalued.
Does Adaptive Biotechnologies Corp pay dividends?
Adaptive Biotechnologies Corp does not currently pay dividends.
What is Adaptive Biotechnologies Corp’s EPS estimate?
Adaptive Biotechnologies Corp’s EPS estimate is -0.3.
How many shares outstanding does Adaptive Biotechnologies Corp have?
Adaptive Biotechnologies Corp has 147,579,480 shares outstanding.
What happened to Adaptive Biotechnologies Corp’s price movement after its last earnings report?
Adaptive Biotechnologies Corp reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.256. Following the earnings report the stock price went down -3.205%.
Which hedge fund is a major shareholder of Adaptive Biotechnologies Corp?
Currently, no hedge funds are holding shares in ADPT
---
Adaptive Biotechnologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.79 (5.52% Upside)
$8.79 (5.52% Upside)
Blogger Sentiment
Bullish
ADPT Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 2.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
111.42%
12-Months-Change
Fundamentals
Return on Equity
-62.44%
Trailing 12-Months
Asset Growth
-18.42%
Trailing 12-Months
Company Description
Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.
---
ADPT Company Deck
---
ADPT Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a positive view of Adaptive Biotechnologies' performance for 2024, highlighting significant growth in MRD revenue, improvements in operational efficiency, and a strong cash position. These positive developments were slightly offset by challenges in the immune medicine segment and a conservative outlook for MRD Pharma Services.Read More>---
ADPT Stock 12 Month Forecast
Average Price Target
$8.79
▲(5.52% Upside)
Technical Analysis
Illumina
―
Crispr Therapeutics AG
―
Guardant Health
―
10x Genomics
―
Beam Therapeutics
―
Best Analysts Covering ADPT
1 Year
1 Year Success Rate
6/8 ratings generated profit
1 Year Average Return
+61.10%
reiterated a buy rating 7 days ago
Copying Rachel Vatnsdal's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +61.10% per trade.
---